Limited coverage drugs – buprenorphine
Special Authority requests can now be submitted online. It's simple and quick!
Learn more or log in.
|
Generic name |
buprenorphine |
|---|---|
|
Strength |
100 mg/0.5 mL, 300 mg/1.5 mL |
|
Form |
extended-release subcutaneous injection |
|
Special Authority criteria |
Approval period |
|---|---|
|
For the management of moderate to severe opioid use disorder in adult patients. Patients must be induced and clinically stabilized on an equivalent of 8 mg to 24 mg of transmucosal buprenorphine-naloxone for a minimum of seven days. |
1 year |
Practitioner exemptions
- None
Special notes
- Patients are under the care of a health care provider with experience in the diagnosis and management of opioid use disorder
- As stated in the Health Canada indication, buprenorphine extended-release injection should be used as part of a complete treatment plan that includes counselling and psychosocial support
- As stated in the Health Canada indication, buprenorphine extended-release injection must be administered subcutaneously in the abdominal region by a healthcare provider
